Marvel's Phase 1 program, which will be developed in collaboration with Contract Research Organization ("CRO") partner Novotech, will evaluate MB-204's potential to treat neurodevelopmental disorders such as Rett syndrome and Fragile X, as well as autism spectrum disorder and depression. The partnership is expected to combine Marvel's lead asset, Novotech's expertise in early phase clinical trials, and 5 Horizons' financial and strategic resources to accelerate MB-204's development. Under the terms of the partnership, 5 Horizons Ventures will contribute funding equivalent to 15% of the Company's CRO costs associated with Marvel's upcoming Phase I clinical trial of MB-204. This non-dilutive support is designed to reduce upfront capital requirements while accelerating the Company's transition into human clinical studies.
"We've been conducting due diligence with the Marvel team over the past year, and we're excited to provide an investment for the Phase 1 trial of MB-204" said Aaron Ray, Managing Partner of 5 Horizons Ventures. "We believe the combination of the Marvel team, pre-clinical data, and multiple indications in both rare disease and the central nervous system positions the company for success. We also believe the FDA's recent announcement providing the framework supporting rare diseases will help accelerate the development process."
The Phase I trial, expected to commence in Q2 2026, will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in healthy ...
